Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/120650
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments
Author: Perrin, S.L.
Samuel, M.S.
Koszyca, B.
Brown, M.P.
Ebert, L.M.
Oksdath, M.
Gomez, G.A.
Citation: Biochemical Society Transactions, 2019; 47(2):625-638
Publisher: Portland Press
Issue Date: 2019
ISSN: 0300-5127
1470-8752
Statement of
Responsibility: 
Sally L. Perrin, Michael S. Samuel, Barbara Koszyca, Michael P. Brown, Lisa M. Ebert, Mariana Oksdath, Guillermo A. Gomez
Abstract: Glioblastoma is the deadliest form of brain cancer. Aside from inadequate treatment options, one of the main reasons glioblastoma is so lethal is the rapid growth of tumour cells coupled with continuous cell invasion into surrounding healthy brain tissue. Significant intra- and inter-tumour heterogeneity associated with differences in the corresponding tumour microenvironments contributes greatly to glioblastoma progression. Within this tumour microenvironment, the extracellular matrix profoundly influences the way cancer cells become invasive, and changes to extracellular (pH and oxygen levels) and metabolic (glucose and lactate) components support glioblastoma growth. Furthermore, studies on clinical samples have revealed that the tumour microenvironment is highly immunosuppressive which contributes to failure in immunotherapy treatments. Although technically possible, many components of the tumour microenvironment have not yet been the focus of glioblastoma therapies, despite growing evidence of its importance to glioblastoma malignancy. Here, we review recent progress in the characterisation of the glioblastoma tumour microenvironment and the sources of tumour heterogeneity in human clinical material. We also discuss the latest advances in technologies for personalised and in vitro preclinical studies using brain organoid models to better model glioblastoma and its interactions with the surrounding healthy brain tissue, which may play an essential role in developing new and more personalised treatments for this aggressive type of cancer.
Keywords: brain organoids
clinical trials
glioblastoma
patient-derived tumour biopsies
tumour microenvironment
Rights: © 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Soci
DOI: 10.1042/BST20180444
Grant ID: http://purl.org/au-research/grants/nhmrc/1067405
http://purl.org/au-research/grants/nhmrc/1123816
http://purl.org/au-research/grants/arc/FT160100366
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.